Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/34847
Title: Upadacitinib in end stage renal disease: A case of acute severe ulcerative colitis.
Austin Authors: Hilley, Patrick ;Con, Danny;Choy, Matthew C ;Srinivasan, Ashish ;De Cruz, Peter P 
Affiliation: Gastroenterology and Hepatology
Austin Academic Centre University of Melbourne Parkville Victoria Australia.
Issue Date: Dec-2023
Date: 2023
Publication information: JGH Open : an Open Access Journal of Gastroenterology and Hepatology 2023-12; 7(12)
Abstract: Recent data, indicating that inflammatory bowel disease (IBD) may be a risk factor for future chronic kidney disease, highlight the need to study the safety and clinical effectiveness of advanced IBD therapies in patients with end stage renal disease (ESRD), defined as an eGFR <15 mL/min/1.73m2. Upadacitinib, a selective oral Janus kinase (JAK) 1 inhibitor, has demonstrated efficacy in the management of moderate to severe ulcerative colitis. There is also emerging data indicating that JAK inhibition may be clinically effective in the setting of steroid-refractory acute severe ulcerative colitis (ASUC). There is, however, a lack of "real-world" data documenting the use of JAK inhibitors in patients with ESRD. Here, we report the use of upadacitinib in a patient with ESRD for the management of steroid-refractory ASUC, demonstrating, for the first time, the safe and clinically effective use of upadacitinib in this population.
URI: https://ahro.austin.org.au/austinjspui/handle/1/34847
DOI: 10.1002/jgh3.13015
ORCID: 0000-0001-5952-1570
Journal: JGH Open : an Open Access Journal of Gastroenterology and Hepatology
Start page: 1012
End page: 1015
PubMed URL: 38162859
ISSN: 2397-9070
Type: Journal Article
Subjects: acute severe ulcerative colitis
end stage renal disease
janus kinase inhibitor
upadacitinib
Appears in Collections:Journal articles

Show full item record

Page view(s)

10
checked on Apr 16, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.